Haemonetics (NYSE:HAE) Updates FY 2027 Earnings Guidance

Haemonetics (NYSE:HAE) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 5.258-5.307 for the period, compared to the consensus estimate of 5.290. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Haemonetics Stock Up 1.7%

NYSE HAE traded up $0.92 on Friday, hitting $55.29. 723,439 shares of the company were exchanged, compared to its average volume of 827,378. The company has a market cap of $2.57 billion, a PE ratio of 15.21, a PEG ratio of 1.03 and a beta of 0.53. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The stock has a fifty day moving average of $59.53 and a 200-day moving average of $66.68. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. During the same quarter last year, the firm posted $1.24 EPS. Haemonetics’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts forecast that Haemonetics will post 4.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on HAE shares. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Mizuho decreased their price target on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Citigroup cut their price target on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a research note on Friday. Finally, Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $79.89.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q4 results beat consensus: Haemonetics reported $1.29 EPS and $346.4M revenue (both ahead of Street estimates), with revenue up ~4.8% year-over-year — a core reason investors are bidding the stock up. Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
• Positive Sentiment: Management expects FY2027 revenue growth of 4%–7%, citing continued Persona PLUS rollout and efforts to rebound IVT volumes — these operational drivers support the growth narrative that investors are rewarding. Haemonetics projects FY 2027 revenue growth of 4% to 7%…
• Positive Sentiment: Outside buying signal: The London Company’s Small Cap Portfolio added to Haemonetics following recent volatility, indicating some institutional interest that can lift sentiment and trading. The London Company Small Cap Portfolio Q1 2026 Portfolio Review
• Neutral Sentiment: FY2027 EPS guidance band (5.258–5.307) is roughly in line with consensus (about 5.29), so while guidance supports stability, it doesn’t represent a clear upside surprise versus expectations. PR Newswire: Financial results available
• Neutral Sentiment: Investors can review the full earnings call transcript and supplemental materials for management commentary and cadence on Persona PLUS and IVT recovery; these details will shape whether the current upbeat reaction sustains. Haemonetics Q4 2026 Earnings Call Transcript

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC lifted its stake in Haemonetics by 48.6% in the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Haemonetics by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after buying an additional 26,763 shares in the last quarter. Millennium Management LLC grew its position in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares in the last quarter. Boston Partners increased its stake in Haemonetics by 5.1% in the 3rd quarter. Boston Partners now owns 570,891 shares of the medical instruments supplier’s stock worth $28,017,000 after acquiring an additional 27,722 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Haemonetics by 17.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 453,930 shares of the medical instruments supplier’s stock valued at $33,868,000 after acquiring an additional 68,326 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.